Forbes " ICPT Doesn't Have Details on Reverse Reactions, Could Stumble" LINK
A $4 Billion Surprise For 45-Person Biotech
Updated Jan. 10, 2014 12:18 a.m. ET
Dr. Pruzanski said the company doesn't yet have details about any adverse events patients might have experienced during the trial.
The drug was invented by Roberto Pellicciari, a professor at the University of Perugia in Italy and a co-founder of the company. Dr. Pellicciari couldn't be reached for comment Thursday.
Many experimental drugs fail to make it to market, so Intercept's OCA could yet stumble. But the clinical trial outcome raised investors' expectations that the company could have a big-selling product on its hands.